Jemperli (DOSTARLIMAB)
Jemperli (DOSTARLIMAB) is one of 8,063 medications in the MedPlain dataset. Key details — Brand name: Jemperli; Generic name: DOSTARLIMAB; Drug class: Programmed Death Receptor-1 Blocking Antibody [EPC].
| Brand name | Jemperli |
|---|---|
| Generic name | DOSTARLIMAB |
| Drug class | Programmed Death Receptor-1 Blocking Antibody [EPC] |
| Manufacturer | GlaxoSmithKline LLC |
| Used for | 1 INDICATIONS AND USAGE JEMPERLI is a programmed death receptor-1 (PD-1)–blocking antibody indicated: Endometrial Cancer • in combination with carboplatin and paclitaxel, followed by JEMPERLI as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial cancer (EC). ( 1.1 ) • as a single agent for the treatment of adult patients with mismatch repair deficient (dMMR) recurrent or advanced EC, as determined by an FDA-approved test, that has progressed on or following prior treatment with a platinum-containing regimen in any setting and are not candidates for curative surgery or radiation. ( 1.1 , 2.1 ) Mismatch Repair Deficient Recurrent or Advanced Soli |
| Dosage | 2 DOSAGE AND ADMINISTRATION • JEMPERLI, in combination with carboplatin and paclitaxel, for primary advanced or recurrent EC: 500 mg every 3 weeks for 6 cycles followed by 1,000 mg monotherapy every 6 weeks for all cycles thereafter. ( 2.2 ) • JEMPERLI, as a single agent, for dMMR recurrent or advanced EC: 500 mg every 3 weeks for 4 cycles followed by 1,000 mg every 6 weeks for all cycles thereafter. ( 2.2 ) • JEMPERLI, as a single agent, for dMMR recurrent or advanced solid tumors: 500 mg every |
| Active ingredient(s) | DOSTARLIMAB |
| Route | INTRAVENOUS |
| Official label | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=095eab9f-545a-4f12-bfb7-19477fb901a5 |